[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,40,0,25,[9,54,91,106,137,165,188,214,239,274,294,322,340,371,397,425,458,485,508,525,553,575,593,613,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":4,"leadSponsor":50,"locationsCount":53},"100133849","the-natural-history-of-severe-viral-infections-and-characterization-of-immune-defects-in-patients-without-known-immunocompromise-100133849",false,"NCT01011712","The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise","The Natural History of Severe Viral Infections and Characterization of Immune Defects","* INCLUSION CRITERIA:\n\n(Participants)\n\nParticipants must meet all the following inclusion criteria in order to participate in this study:\n\n1. Children or adults (regardless of age) with a definitively diagnosed severe or unusual viral infection, including but not limited to infections caused by herpesviruses (HSV-1, HSV-2, CMV, EBV, VZV, HHV-6, HHV-7, HHV-8), human papillomavirus (e.g., severe recalcitrant warts), adenovirus, calicivirus (e.g. norovirus), polyomavirus (such as JC virus and BK virus), or influenza virus. Viral infections that would be considered opportunistic-like , such as herpesvirus esophagitis, herpesvirus encephalitis, CMV colitis, or progressive multifocal leukoencephalopathy (caused by the JC polyoma virus) will be of particular interest in this protocol.\n\n   OR\n\n   Children or adults with a well-documented prior, severe, persistent, or treatment-refractory viral infection(s), who have clinically recovered from the viral infection.\n2. Ongoing care by a referring physician.\n3. Willingness to allow storage of blood and tissue samples for future analyses.\n\n(Relatives)\n\nRelatives (2 years or above) may be recruited and enrolled to improve interpretation of genetic results, to expand the phenotype of the suspected or confirmed inborn error of immunity in the proband with severe viral infection, and to understand the co-factors in affected and\u002For unaffected family members that may influence variable expressivity and penetrance of viral infections in inborn errors of immunity.\n\n1. Males and females will be accepted.\n2. Relatives may either be healthy or have features concerning for an inborn error of immunity including, but not limited to, autoimmunity, severe atopy, other forms of immune-dysregulation, or severe or unusual infections. While the enrolled proband must have a current or prior severe or unusual viral infection, family members who are suspected to have an inborn error of immunity do not need to have a history of severe or unusual viral infection in the presence of other features suspicious for inborn errors of immunity.\n3. Adult relatives or the guardians of minor relatives must be willing and capable of providing informed consent after review of protocol procedures that are described in the consent form with an appropriate study team member.\n4. Participating relatives agree to have blood stored for future studies of the immune system.\n\nEXCLUSION CRITERIA:\n\nParticipants meeting any of the following exclusion criteria at baseline will be excluded from study participation:\n\n1. Patients with previously diagnosed conditions associated with acquired or iatrogenic immunodeficiency and\u002For immunosuppresion (e.g., a history of HIV infection, a positive test for HIV, chemotherapy or high dose glucocorticoids). Patients on immunosuppression and\u002For immunomodulatory therapy for the treatment of conditions that may be attributable to an underlying inborn error of immunity may be included in the study at the discretion of the PI or their designee.\n2. Women who are pregnant.\n3. Any condition or major comorbidity that the study investigators believe will compromise the patient's ability to comply with the requirements of the study.","ALL","2 Years","100 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","Background:\n\n* Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore throats, chicken pox, and the flu are caused by different viruses. Usually, these illnesses last only few days or, at most, a few weeks. Some virus infections like influenza are cleared from the body, and others such as the chicken pox virus remain in the body in an inactive state. However, some people may become quite ill when they are infected with a particular virus, possibly because part of their immune system does not respond properly to fight the virus.\n* Researchers have discovered some reasons why a person may not be able to clear an infection caused by a virus. Some persons have changes in the genes that involve the immune system that result in the inability to properly control infection with a particular virus. Identifying changes in genes that involve the immune system should help scientists better understand how the immune system works to protect people from infection and may help develop new therapies.\n\nObjectives:\n\n* To study possible immune defects that may be linked to a particular severe viral infection.\n* To determine if identified immune defects are genetic in origin.\n\nEligibility:\n\n* Individuals of any age who have or have had a diagnosis of a virus infection that physicians consider to be unusually severe, prolonged, or difficult to treat.\n* Relatives of the participants with a severe viral infection may also participate in the study. We will use their blood and\u002For skin specimens to try to determine if identified immune defects are hereditary.\n\nDesign:\n\n* Prior to the study, the participant's doctor will give researchers the details of the infection, along with medical records for review. Eligible participants will be invited to the NIH Clinical Center for a full evaluation as an outpatient or inpatient.\n* At the Clinical Center, participants will be treated with the best available therapy for the particular viral infection, and researchers will monitor how the infection responds to the treatment.\n* Researchers will take intermittent blood samples and conduct other tests (such as skin biopsies) to evaluate the immune system. - During and after the illness, researchers will conduct follow-up visits to determine the course of infection and response to therapy.",[26,27,28,29,30],"EBV","HSV","VZV","HPV","CMV",[32,33,34,35,36,37,38,39,40,41,42],"Genetics","Virus","Defense","Immunity","Immunodeficiency","Natural History","Respiratory Viruses","Herpesvirus","Cytomegalovirus","Human Papillomavirus","Adenovirus","RECRUITING","2026-06-17",{"date":46,"type":47},"2026-06-18","ACTUAL",{"date":49,"type":47},"2009-10-01",{"name":51,"class":52},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":53},"100642783","feasibility-study-comparing-one-vs-two-probes-for-thermal-ablation-among-cervical-cancer-screen-positive-wlwh-in-c1001p-cs9-south-africa-100642783","NCT07645378","Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South Africa","Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV","Inclusion Criteria:\n\n1. 25-49 years old\n2. Living with HIV\n\nInclusion criteria specific to the feasibility study\n\n1. Intact cervix\n2. Willing to return to facility at 6 months\n3. Willing and able to provide informed consent\n4. Positive hrHPV or VIA test within 3 months of enrollment\n5. Type 1 transformation zone (TZ1)\n6. Thermal ablation eligible\n\nExclusion Criteria:\n\n1. Screened for cervical cancer outside of study in last 6 months\n2. Currently pregnant or less than 6 weeks postpartum\n3. Prior diagnosis of cervical cancer\n4. A history of treatment for cervical precancer\n5. Total hysterectomy\n6. Currently receiving treatment for any cancer\n7. Individual has a condition that the Clinical Site PI believes will interfere with or affect the conduct, results, or completion of the clinical study\n8. Individual has a condition that the Clinical Site PI considers creates an unacceptable risk to the individual if enrolled","FEMALE","25 Years","49 Years",{"count":65,"type":22},200,"INTERVENTIONAL",[68],"NA","Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030.",[71,29,72,73],"HIV (Human Immunodeficiency Virus)","Cervical Precancer","Cervical Neoplasia",[75,76,77,78,79],"HIV","Cervical cancer screening","Treatment of Cervical Precancer","Thermal ablation","Human papillomavirus","NOT_YET_RECRUITING","2026-06-09",{"date":83,"type":47},"2026-06-12",{"date":85,"type":22},"2026-06",{"date":87,"type":22},"2027-05-31",{"name":89,"class":90},"Fred Hutchinson Cancer Center","OTHER",{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":96,"targetDuration":4,"studyType":66,"phases":98,"briefSummary":99,"conditions":100,"keywords":101,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":105,"locationsCount":53},"100643388","feasibility-study-comparing-one-vs-two-probes-for-thermal-ablation-among-cervical-cancer-screen-positive-women-living-with-hiv-in-c1001p-cs7-zimbabwe-100643388","NCT07645352","Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS7 Zimbabwe",{"count":97,"type":22},300,[68],"Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. While thermal ablation (TA) is a WHO- recommended treatment for cervical precancerous lesions, its efficacy can be suboptimal in WLWH. We will also conduct a feasibility treatment cohort study of up to 300 Zimbabwean WLWH to provide evidence for a larger treatment effectiveness study. The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings and to contribute towards achieving the 90-70-90 goals of the World Health Organization's (WHO) strategy for accelerated elimination of cervical cancer as a public health problem by 2030.",[71,29,72,73],[75,76,77,78,79],{"date":83,"type":47},{"date":85,"type":22},{"date":87,"type":22},{"name":89,"class":90},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":66,"phases":117,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100643606","addressing-hpv-vaccine-hesitancy-by-co-designing-a-digital-health-intervention-100643606","NCT07632963","Addressing HPV Vaccine Hesitancy by Co-Designing a Digital Health Intervention","HPV-Kompassen: a Mixed-Methods Single-Arm Cluster Feasibility Study of a Co-Designed Web-Based Intervention To Strengthen HPV Vaccine Confidence and Uptake in Stockholm, Sweden","HPV-END-IT","We will aim to recruit 6-8 compulsory schools in Stockholm County to serve as clusters.\n\nAll Year 5 pupils and their caregivers in the study schools are invited.\n\nInclusion Criteria:\n\n* The school provides education to pupils in school year 5 and is scheduled to be open throughout the pilot trial period\n* The school is located in an area with HPV vaccine uptake \\\u003C85.2% (the Stockholm regional average)\n* The head principal and school nurse both consent to participate\n* The school has the capacity to implement the intervention\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria",true,{"count":116,"type":22},100,[68],"This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated.\n\nResearchers will give Year 5 pupils (aged 11-12) and their parents or caregivers access to the platform. It provides clear, trusted information about the HPV vaccine for young people, parents, and school nurses. The aim is to make the vaccine easier to understand and to help answer any questions or concerns.\n\nAfter using the platform, participants will be asked to share their thoughts.",[29,120,121,122],"Vaccine Acceptance","Vaccine Decision Making","HPV Vaccination",[124,125,126,127],"Human papilloma virus","HPV vaccine","Vaccine uptake","Vaccine confidence","2026-06-02",{"date":130,"type":47},"2026-06-08",{"date":132,"type":22},"2026-08",{"date":134,"type":22},"2027-06",{"name":136,"class":90},"Karolinska Institutet",{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":114,"sex":61,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":66,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100640905","effect-of-web-based-education-on-attitudes-and-beliefs-about-hpv-testing-100640905","NCT07620795","Effect of Web-Based Education on Attitudes and Beliefs About HPV Testing","THE EFFECT OF WEB-BASED EDUCATION GIVEN TO WOMEN ON THEIR ATTITUDES AND BELIEFS ABOUT HPV TESTING","Inclusion Criteria:\n\n* Having no prior clinical diagnosis of cervical cancer\n* Being between 18 and 60 years of age\n* Having active access to the internet\n* Being literate at a level sufficient to read and understand the questionnaire forms\n* Being capable of effectively navigating and using a web browser\n* Being registered as a patient at Sakarya Akyazı No. 3 Family Health Center\n* Volunteering to participate in the study and providing informed consent\n\nExclusion Criteria:\n\n* Withdrawing from the study voluntarily at any stage\n* Failing to watch the mandatory educational videos on the platform\n* Submitting incomplete or incorrect responses to the data collection tools\n* Lacking active internet access or proper web browser usage skills\n\nCriteria for Study Discontinuation \u002F Drop-out:\n\n* Participant's request to withdraw from the study\n* Failure to respond to or complete the data collection tools\n* Not using or logging into the web application for more than 2 consecutive weeks during the study period","18 Years","60 Years",{"count":147,"type":22},120,[68],"Cervical cancer is a highly preventable public health issue that significantly impacts women's quality of life. Although effective screening programs such as Human Papilloma Virus (HPV) testing and Pap-smears are widely available, women's participation in these early detection services often remains limited. The primary barriers to screening attendance include insufficient education, lack of information, negative beliefs, psychosocial or cultural factors, and misconceptions regarding gynecological examinations. To improve screening uptake, health interventions must focus not only on increasing knowledge but also on promoting correct beliefs and positive attitudes toward testing.\n\nWeb-based health education serves as an effective method to overcome barriers such as cost, transportation difficulties, and geographical limitations, allowing wider access to healthcare guidance. This study aims to evaluate the effects of a specialized web-based educational intervention on women's attitudes and beliefs regarding the HPV test. The research is designed as a randomized controlled trial with a pre-test and post-test design. Participants will be assigned to either an intervention group or a control group. The intervention group will receive structured health education through a dedicated web platform, while the control group will receive routine standard follow-up. Data will be gathered using a specific attitude and belief scale before and after the application to measure the intervention's impact.",[151,29],"Cervical Cancer",[153,154,155,156],"HPV Testing","Health Education","Web-based learning","Attitudes and Beliefs","2026-05-27",{"date":128,"type":47},{"date":160,"type":22},"2026-07-01",{"date":162,"type":22},"2026-09-01",{"name":164,"class":90},"Sakarya University",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":114,"sex":17,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":66,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":53},"100545300","stand-up-2-hpv-standing-orders-to-improve-hpv-vaccination-100545300","NCT06380114","Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination","Inclusion Criteria:\n\n* active patient in AHP practice\n\nExclusion Criteria:\n\n* patient belonging to a practice with \\>80% UTD baseline HPV vaccination rate for ages 13-17\n* patient belonging to a practice with \\\u003C20 11-12 year-olds eligible for an HPV dose","9 Years","17 Years",{"count":174,"type":22},16000,[68],"Each year in the U.S., ≥20,000 women and 14,000 men are affected by HPV-related cancers, including cervical and oropharyngeal cancer. However, in 2020, only 59% of U.S. adolescents aged 13-17 were up-to-date for HPV vaccination, and rates for 11-12 year olds, the primary target age group for HPV vaccination (when the immune reaction is better and before exposure to HPV infection), are even lower. Standing orders (written protocols that authorize designated members of the healthcare team to vaccinate without first obtaining a patient-specific physician order) have been shown to work in inpatient settings and for adults, but have not been evaluated for HPV vaccine, which some parents consider controversial. Also, the ways in which organizational readiness for change (resources, motivation, staff attributes, leadership support and culture) moderate the effect of standing orders has not been studied. A physician's recommendation is correlated with HPV vaccine acceptance, and the investigators have developed a successful online, interactive, communication education program that will be adapted to train nurses and staff in addition to physicians. The investigators propose testing standing orders for HPV vaccine in an Accountable Care Organization (ACO) in Western New York, and assessing which provider and practice factors moderate the effect of standing orders. Advantages of this setting include a diverse group of rural, urban and suburban practices, and the ACO provides data infrastructure and analytics that allow practices to evaluate vaccination rates in real time.\n\nUsing a 2-arm cluster randomized trial (n=40 practices), the investigators will assess the effectiveness of standing orders (SO) + HPV communication education (intervention arm) relative to HPV communication education alone (control arm) on HPV vaccination for 9-17 year-olds.",[178],"Hpv","2026-05-26",{"date":181,"type":47},"2026-05-29",{"date":183,"type":47},"2024-11-04",{"date":185,"type":22},"2028-05",{"name":187,"class":90},"University of Rochester",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":114,"sex":17,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":66,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100631238","digital-interventions-to-increase-hpv-vaccination-intentions-among-nigerian-caregivers-100631238","NCT07498075","Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers","A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers","Inclusion Criteria:\n\n* Parent or primary caregiver of at least one girl aged 9-14 years\n* Parent states \"no\" or \"unsure\" to question asking if eligible daughter has received any doses of the HPV vaccine\n* Provides informed consent to participate\n\nExclusion Criteria:\n\n* Parent or caregiver of a girl who has already received one or more doses of the HPV vaccine\n* Does not meet age eligibility criteria for an eligible daughter\n* Fails Attention Checks","27 Years",{"count":197,"type":22},3340,[68],"This study evaluates whether different types of digital health communication can increase parents' intention to vaccinate their daughters against human papillomavirus (HPV) in Nigeria. HPV vaccination is recommended for girls aged 9-14 years and helps prevent cervical cancer, yet vaccination rates remain low.\n\nParents of eligible, unvaccinated girls will be randomly assigned to receive one of several types of digital content delivered online. These include: (1) a short chatbot conversation based on motivational interviewing principles, (2) an interactive game designed to help parents recognize and resist common forms of vaccine misinformation, (3) a set of short edutainment videos about HPV vaccination, (4) standard informational infographics about HPV vaccination from a national public health agency, or (5) unrelated health content about menstruation.\n\nThe main outcome is parents' self-reported intention to vaccinate their daughter against HPV, measured immediately and one week after exposure to the assigned content. Additional outcomes include HPV-related knowledge, perceptions of vaccine safety, willingness to recommend the vaccine to others, and self-reported vaccine uptake at 1-week and 6 month follow-up. The results will help inform scalable communication strategies to improve HPV vaccination uptake in low- and middle-income settings.",[29,201],"HPV Vaccine",[29,201,203,204,205],"Chatbots","Misinformation","Pre-Bunking","2026-05-18",{"date":208,"type":47},"2026-05-20",{"date":206,"type":22},{"date":211,"type":22},"2026-12-31",{"name":213,"class":90},"University of Pennsylvania",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":114,"sex":17,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":66,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":53},"100514926","playing-game-to-learn-about-childrens-vaccine-project-100514926","NCT05984849","Playing Game to Learn About Children's Vaccine Project","A Pilot Randomized Controlled Study to Examine Feasibility and Preliminary Effectiveness of a Game-based Intervention in Promoting HPV Vaccination Among Vulnerable Youth to Prevent Cancers","Inclusion Criteria:\n\n* Child sample: (1) 11-14 years old, (2) speaks and reads English, (3) has never received any doses of the HPV vaccine, (4) is not currently enrolled in another project that involves HPV-related education, and (5) agrees and provides assent to participate in research activities.\n* Parent sample: (1) parent or legal guardian of the participating child, (2) speak and read English, (3) own a smartphone, (4) agree to receive email and text messages, (5) is not currently enrolled in another project that involves HPV-related education, and (6) agree and provide consent to participate in research activities.\n\nExclusion Criteria: Individuals who do not meet inclusion criteria or refuse to provide consent\u002Fassent.","11 Years","14 Years",{"count":224,"type":22},180,[68],"This proposed study aims to conduct timely research that promotes vaccine confidence and vaccination of one strongly recommended vaccine with suboptimal uptake rates: Human papillomavirus (HPV) in vulnerable and underserved youth aged 11-14.",[29,228],"Vaccine-Preventable Diseases",[230,231],"adolescent","game intervention",{"date":208,"type":47},{"date":234,"type":47},"2025-10-27",{"date":236,"type":22},"2027-08-31",{"name":238,"class":90},"Michigan State University",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":247,"minAge":248,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":66,"phases":251,"briefSummary":252,"conditions":253,"keywords":259,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":273},"100595184","screening-for-anal-cancer-in-men-who-have-sex-with-men-using-pre-exposure-prophylaxis-100595184","NCT07029152","Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis","Screening for Anal Cancer in MSM Using PrEP","SCOPE","Inclusion Criteria:\n\n* HIV-uninfected MSM (men who have sex with men) aged 35 years or older.\n* participants must have been using PrEP for at least 3 months.\n* Dutch, English or French speaking and writing\n\nExclusion Criteria:\n\n* Any intervention in the (peri-)anal region within the past 3 months\n* Enema usage within 2 h before sampling\n* Currently undergoing peri-anal topical HPV-treatment\n* HRA in the last year (anal swab or HRA prior to the last year is no exclusion)","MALE","35 Years",{"count":250,"type":22},296,[68],"This study aims to learn more about anal cancer risk in men who have sex with men (MSM) who are using Pre-Exposure Prophylaxis (PrEP) to prevent HIV. Specifically, we want to check how common High-Grade Squamous Intraepithelial Lesions (HSIL) are in this group, how well anal swabs can screen for these lesions, and how having HSIL affects their quality of life. We'll also test if DNA methylation testing can give us extra information about the lesions.\n\nThe main questions the study aims to answer are:\n\n* How common are HSIL in MSM using PrEP?\n* How accurate are anal swabs for detecting HSIL in this group?\n* How does having HSIL affect the quality of life of MSM using PrEP?\n* Can DNA methylation testing help improve our understanding of HSIL in these individuals?\n\nParticipants will:\n\n* Answer questions about their health and quality of life.\n* Have an anal smear collected for testing.\n* Undergo High-Resolution Anoscopy (HRA) to check for HSIL and get a biopsy if deemed necessary.",[254,255,256,257,29,258],"Anal Cancer","Squamous Intraepithelial Lesions","HSIL, High Grade Squamous Intraepithelial Lesions","LSIL, Low-Grade Squamous Intraepithelial Lesions","Squamous Cell Carcinoma",[260,261,262,263],"HIV prevention","men who have sex with men","pre-exposure prophylaxis (PrEP)","anal cancer","2026-04-30",{"date":266,"type":47},"2026-05-01",{"date":268,"type":47},"2025-09-23",{"date":270,"type":22},"2026-12",{"name":272,"class":90},"Universitair Ziekenhuis Brussel",8,{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":114,"sex":61,"minAge":171,"maxAge":172,"enrollmentInfo":281,"targetDuration":4,"studyType":66,"phases":282,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100636230","a-bio-psycho-social-medical-model-based-study-on-adolescent-female-hpv-vaccination-behavior-and-comprehensive-intervention-100636230","NCT07562984","A Bio-Psycho-Social Medical Model-Based Study on Adolescent Female HPV Vaccination Behavior and Comprehensive Intervention","A Bio-Psycho-Social Medical Model-Based Study on Adolescent Female HPV Vaccination Behavior and Comprehensive Intervention: An International Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female, aged 9-17 years (inclusive of 9 and 17 years old).\n2. Attending pediatric \\& adolescent gynecology, adolescent health clinics, or related pediatric\u002Fchild healthcare clinics at the research centers; or attending vaccination clinics for non-HPV vaccinations (e.g., influenza, tetanus).\n3. Has not received any dose of HPV vaccine and has no definitive plan for HPV vaccination on the day of the visit (confirmed by investigator inquiry).\n4. Accompanied by at least one primary caregiver (parent or legal guardian) who can comprehend the study content and is willing to participate in shared decision-making interventions.\n5. Plans to reside mostly in the region where the research center is located for the next 12 months to facilitate follow-up.\n6. Caregiver provides written informed consent; adolescent provides informed consent\u002Fassent per local ethical requirements.\n\nExclusion Criteria:\n\n1. Previous completion of or initiation of any HPV vaccine series.\n2. History of severe allergic reaction to any HPV vaccine or its main components, or assessed by a vaccinating physician as currently unsuitable for HPV vaccination.\n3. Comorbid severe physical illness (e.g., severe cardiopulmonary disease, active malignancy) or severe mental disorder, judged by the investigator as unsuitable for participation or likely unable to complete follow-up.\n4. Participation in other clinical studies highly related to HPV vaccination behavior intervention within the past year, which may interfere with the evaluation of this study's intervention effect.\n5. Currently receiving treatment for HPV-related diseases (e.g., genital warts) where the physician considers vaccination currently inadvisable.\n6. History of autoimmune diseases or tumors.\n7. Other situations deemed by the investigator to affect study adherence or interpretation of results (e.g., families with extremely high mobility).",{"count":97,"type":22},[68],"Based on the biopsychosocial (BPS) medical model, this study focuses on HPV vaccination behavior among adolescent females. It aims to explore the influence of multidimensional factors-including biological characteristics, psychological factors, and family and social environments-on vaccination behavior, and to evaluate the effectiveness of a comprehensive HPV vaccination intervention program designed for joint participation by adolescents and their parents.\n\nThis study employs a prospective, multicenter, randomized, open-label, parallel-group design. Participants-girls and adolescents aged 9-17 who are scheduled to receive or have not yet completed HPV vaccination, along with their primary caregivers-were recruited from our hospital and collaborating pediatric\u002Fmaternal and child health institutions both domestically and internationally. Participants were randomly assigned in a 1:1 ratio to an intervention group and a control group.\n\nIn addition to routine vaccination clinic counseling, the intervention group received a comprehensive HPV vaccination intervention program based on the BPS model, including: structured health education materials (illustrated booklets\u002Fshort videos); structured communication and shared decision-making support in the clinic setting; continuous information dissemination and vaccination reminders via platforms such as WeChat; and personalized follow-up and Q\\&A sessions for families with high vaccine hesitancy; The control group received standard routine education and vaccination services.\n\nThe primary outcome was the proportion of adolescents who completed the first dose of the HPV vaccine within 3 months of enrollment; secondary outcomes included the proportion completing the full vaccination series within 6 months, changes in vaccine hesitancy levels and HPV-related knowledge, changes in anxiety\u002Fdepression levels among adolescents and caregivers, and changes in the quality of parent-child communication regarding health and vaccination as well as family decision-making patterns.\n\nThis study is expected to identify key bio-psycho-social determinants of HPV vaccination behavior among adolescent females, validate the effectiveness of the comprehensive BPS intervention in increasing vaccination rates and improving decision-making experiences and psychosocial outcomes, and provide evidence-based guidance and scalable practical pathways for pediatric and related specialty clinics to implement adolescent vaccination health promotion and family shared decision-making services.",[29,285,286],"Vaccination Hesitancy","Biopsychosocial Model","2026-04-28",{"date":266,"type":47},{"date":264,"type":22},{"date":291,"type":22},"2028-11-30",{"name":293,"class":90},"The Children's Hospital of Zhejiang University School of Medicine",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":114,"sex":61,"minAge":301,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":66,"phases":304,"briefSummary":305,"conditions":306,"keywords":311,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":53},"100619536","emergency-department-based-cervical-cancer-screening-through-self-sampling-100619536","NCT07345897","Emergency Department-based Cervical Cancer Screening Through Self-sampling","Advancing Cervical Cancer Screening Through Emergency Department-based Self-Sampling","Inclusion Criteria:\n\n* Cisgender women and transgender\u002Fnon-binary individuals with a cervix,\n* Age 30 - 65 years, and demonstrating decisional capacity to consent to participate with no known exclusion criteria present.\n\nExclusion Criteria:\n\n* Past hysterectomy with cervical removal\n* Known infection with HIV (as screening recommendations for people with HIV differ from the general population)\n* Inability to consent (e.g., lacking decisional capacity, intoxicated, or in distress)\n* Current pregnancy or in the three months after giving birth\n* Use of vaginal ovules, creams or washes, vaginal contraceptives or condoms within past 3 days\n* Sexual intercourse or transvaginal ultrasound scans or gynecological examinations within past 2 days","30 Years","65 Years",{"count":65,"type":22},[68],"This project will compare the uptake of cervical cancer screening through ED HPV sampling among patients presenting to the ED.",[29,307,308,309,310],"HPV Associated Cancers","HPV Cancers","Cervical Cancer Screening","Cervical Cancer (Early Detection)",[312,76,29,313],"HPV Screening","Cervical cancer","2026-04-27",{"date":316,"type":47},"2026-05-04",{"date":318,"type":47},"2026-02-13",{"date":320,"type":22},"2028-01",{"name":187,"class":90},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":327,"targetDuration":4,"studyType":66,"phases":328,"briefSummary":329,"conditions":330,"keywords":331,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":53},"100622999","feasibility-study-comparing-one-vs-two-probes-for-ta-among-cervical-cancer-screen-positive-wlwh-in-c1001p-cs5-rwanda-100622999","NCT07390916","Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 Rwanda",{"count":97,"type":22},[68],"Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. This is even more important at a time when Rwanda has launched a National Cervical Cancer Screening Program (NCCSP) with human papillomavirus (HPV) testing and treatment, mainly using TA with unknown outcomes. Therefore, we will conduct a feasibility study (C1001P-CS5) among 300 Rwandan WLWH to provide evidence needed to launch a future effectiveness study. The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030. Rwanda hopes to achieve this goal early, in 2027 under Mission 2027.",[71,29,72],[75,76,77,78,79],"2026-04-24",{"date":334,"type":47},"2026-04-29",{"date":336,"type":22},"2026-05-31",{"date":338,"type":22},"2028-05-31",{"name":89,"class":90},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":66,"phases":349,"briefSummary":351,"conditions":352,"keywords":357,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":370},"100477019","phase-2-a-study-of-reduced-radiation-therapy-and-standard-of-care-chemotherapy-in-people-with-hpv-positive-throat-cancer-100477019","NCT05491512","A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma","Inclusion Criteria:\n\n* Pathologically (histologically or cytologically) proven diagnosis of HPV associated squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or oropharyngeal walls) from biopsy, surgical resection or excisional biopsy regardless of margin status.\n\n  1. Squamous cell carcinoma of the neck of unknown primary is allowed with excision biopsy of a lymph node (or core biopsy) or consent from the PI or co-PI\n  2. Patient must have excisional biopsy or core biopsy done in order to be on protocol\n* Subjects must have clinically or radiographically evident measurable gross disease at either the primary tumor site or nodal stations.\n* Oropharyngeal Carcinoma (AJCC, 7th ed.) without evidence of distant metastasis based on FDG PET\u002FCT.\n* CT or MRI of the neck with and without contrast Note: A CT scan of neck and\u002For a PET\u002FCT performed for the purposes of radiation planning may serve as planning tools.\n* ECOG Performance Status of 0-2 or KPS ≥ 50\n* Age ≥ 18 Patients over 70yrs will be able to enroll in Cohort B only).\n* Adequate hematologic function within 30 days prior to registration, defined as follows:\n\n  1. White Blood Count (WBC) ≥ 2 K\u002FmcL\n  2. Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm3\n  3. Platelets ≥ 100,000 cells\u002Fmm3\n  4. Hemoglobin ≥ 8.0 g\u002Fdl; Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002Fdl is acceptable\n* Adequate renal function within 30 days prior to registration, defined as follows:\n\n  1. Serum creatinine \\\u003C 1.5 mg\u002Fdl or creatinine clearance (CC) ≥ 50 ml\u002Fmin determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = \\[(140 - age) x (wt in kg)\\] \\[(Serum Cr mg\u002Fdl) x (72)\\] CCr female = 0.85 x (CrCl male)\n\nNote: Patients who cannot tolerate cisplatin or carboplatin\u002F5FU based on clinical judgment will receive carboplatin and paclitaxel Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel).\n\n* Adequate hepatic function within 30 days prior to registration, defined as follows:\n\n  1. Bilirubin \\\u003C 2 mg\u002Fdl\n  2. AST or ALT \\\u003C 3 x the upper limit of normal\n\nNote: Exceptions can be made with PI and\u002For Co-Pi approval for patients to enroll on trial with a higher Bilirubin level such as Gilbert's Syndrome.\n\nNote: Patients who cannot tolerate cisplatin or carboplatin\u002F5FU based on clinical judgment will receive carboplatin and paclitaxel. Paclitaxel can be substituted with Abraxane (Albumin-bound Paclitaxel).\n\n* Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential\n* The subject must provide study-specific informed consent prior to study entry\n* Subject able to undergo MRI scans except for major medical contraindications like presence of a pacemaker or approved by the PI or the CO-PI that the subject does not need to undergo MRI scans\n\nExclusion Criteria:\n\n* Subjects with prior head and neck radiation therapy\n* Subjects with simultaneous primary cancers outside of the oropharynx\n\n  a. Note: Exceptions can be made for patients with simultaneous primaries outside the oropharynx if determined by the PI\u002FCo-PI the patient can proceed with protocol activities.\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years to be 90% or greater\n* Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable\n* Severe, active co-morbidity defined as follows: (exceptions can be made if approved by the PI and\u002For co-PI)\n\n  1. Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months\n  2. Transmural myocardial infarction within the last 6 months\n  3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n  4. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration\n  5. Hepatic Insufficiency resulting in clinical jaundice and\u002For coagulation defects",{"count":348,"type":22},121,[350],"PHASE2","The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, carboplatin, and 5-fluorouracil (5- FU), paclitaxel and abraxane- (Albumin-bound Paclitaxel).",[29,353,354,355,356],"Throat Cancer","Oropharyngeal Carcinoma","Oropharyngeal Cancer","Human Papilloma Virus",[358,29,353,356,354,355,359,360,361],"HPV-Positive Throat Cancer","Radiation Therapy","22-215","Memorial Sloan Kettering Cancer Center","2026-04-22",{"date":364,"type":47},"2026-04-23",{"date":366,"type":47},"2022-08-04",{"date":368,"type":22},"2027-08-04",{"name":361,"class":90},7,{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":66,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":396},"100585458","treatment-de-escalation-for-favorable-prognosis-human-papilloma-virus-hpv-or-p16-positive-oropharyngeal-cancer-receiving-definitive-radiotherapy-100585458","NCT06902623","Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy","A Phase II Study of Treatment De-Escalation for Favorable Prognosis, Stage I-II Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy","Lombardi197","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age on the day of signing informed consent.\n* Patients must have a diagnosis of p16+ and\u002For HPV+ squamous cell carcinoma of the oropharynx (including base of tongue, glossotonsilar sulcus, tonsil, soft palate, vallecula, and\u002For posterior oropharyngeal wall).\n* clinical stage stage I-II (T1-2 N1 M0, or T3 N0-1 M0 ) (AJCC 8th ed.) SCCA of the oropharynx that would mandate definitive chemoradiation as current standard of care when standard radiation fractionation is applied. Debulking of the disease by resecting the exophytic portion of the tumor for biopsy\u002Fsample or symptom alleviation will be permitted, as long as gross unresected tumor is left behind.\n* Subjects must agree to biopsy of areas that are FDG-avid on PET-CT scan 3-4 months after treatment.\n* Patients must have Karnofsky Performance Status (KPS) ≥ 60 within 8 weeks prior to registration\n* Patients must have had a neutrophil:lymphocyte ratio ≤ 5 within 8 weeks of registration.\n* Patient must have had a hemoglobin count ≥ 10 within 8 weeks of registration. The patient may receive transfusion to reach this goal.\n* Patients must be a current non-smoker (at least 6 months) with ≤ 15 pack-year smoking history\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Patients with gross involvement of level 4 lymph node level\n* Endophytic T3 disease, as clinically determined by the principal investigator.\n* Patients with any single lymph node \\> 4cm (multiple lymph nodes including nodal conglomerates that in sum measure \\>4cm is allowed)\n* Patients with nodal disease clinically fixed to or radiographically invading adjacent neck musculature any single lymph node \\> 4cm (multiple lymph nodes including nodal conglomerates that in sum measure \\>4cm is allowed)\n* Prior history of malignancy diagnosed within 2 years prior to registration, except for nonmelanomatous skin cancer that has completed treatment and the patient is deemed as being disease-free, or Gleason 6 prostate cancer undergoing active surveillance.\n* Patients must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.",{"count":380,"type":22},30,[68],"The current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Results with chemotherapy combined with full-dose radiation therapy leads to high rates of cure; this has called into question whether therapy can be decreased in intensity since both chemotherapy and radiation have long-term side effects. One approach to decrease intensity of treatment is to give radiation alone (excluding chemotherapy) and to decrease radiation therapy dose. The investigator believes that omitting chemotherapy and decreasing radiation dose both to tumor and the regions of the head and neck at highest risk of potential spread, may have no significant impact on the cancer recurring while potentially leading to fewer long-term side effects.",[384,29,385,386],"Oropharyngeal Cancers","Tonsil Cancer","Base of Tongue Cancer","2026-04-14",{"date":389,"type":47},"2026-04-17",{"date":391,"type":47},"2019-08-01",{"date":393,"type":22},"2030-12-31",{"name":395,"class":90},"Georgetown University",2,{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":66,"phases":405,"briefSummary":406,"conditions":407,"keywords":412,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":273},"100462919","phase-2-a-study-on-using-cell-free-tumor-dna-ctdna-testing-to-decide-when-to-startroutine-treatment-in-people-with-human-papilloma-virus-hpv--associated-oropharynx-cancer-opc-100462919","NCT05307939","A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)","Phase II Trial Evaluating Selective Minimal Residual Disease Directed Adjuvant Radiation in Human Papilloma Virus Associated Oropharynx Carcinoma","Inclusion Criteria:\n\n* Age ≥ 18\n* ECOG 0-2\n* HPV-16 squamous cell carcinoma of the oropharynx or HPV-16 head and neck squamous cell carcinoma of unknown primary . HPV status must be confirmed by in-situ hybridization.\n* HPV ctDNA detectable by HPV digital PCR (Naveris assay) with a minimum of 50 copies\u002FmL pre-operatively.\n* Surgical resection of all gross disease with no gross disease visualized on post-operative imaging.\n\n  o For patients with pT0 (unknown primary) evaluation for the primary should include PET\u002FCT, direct laryngoscopy, ipsilateral tonsillectomy, and targeted biopsy. This should be followed by a neck dissection.\n* Two, undetectable (\\\u003C1 copy\u002FmL) post-operative HPV ctDNA within 2-6 weeks following surgery (blood drawn at least one week apart preferred).\n* A minimum of one of the following pathologic criteria: (Arm A)\n\n  * AJCC 7 Stage: pT0N1-N2b, pT1N1, pT2N1, or ≥pT3\n  * AJCC 7 ≥pN2\n  * Lymphovascular invasion\n  * Perineural invasion\n  * Close pathologic margin (≤ 3 mm)\n* Signed informed consent form by the participant or their legally authorized representative (LAR).\n* A minimum of one of the following pathologic criteria (Arm B):\n\n  * Microscopic positive margin\n  * Extracapsular extension\n* Signed informed consent form by the participant or their legally authorized representative (LAR).\n\nAdditional criteria for Arm B only:\n\n* Adequate hematologic function within 30 days prior to registration, defined as follows:\n\n  * White Blood Count (WBC) ≥ 2 K\u002FmcL\n  * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002Fmm3\n  * Platelets ≥ 100,000 cells\u002Fmm3\n  * Hemoglobin ≥ 8.0 g\u002Fdl; Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002Fdl is acceptable\n* Adequate renal function within 30 days prior to registration, defined as follows:\n\n  * Serum creatinine \\\u003C 1.5 mg\u002Fdl or creatinine clearance (CC) ≥ 50 ml\u002Fmin determined by 24-hour collection or estimated by Cockcroft-Gault formula:\n  * CCr male = \\[(140 - age) x (wt in kg)\\] divided by \\[(Serum Cr mg\u002Fdl) x (72)\\]\n  * CCr female = 0.85 x (CrCl male)\n* Adequate hepatic function within 30 days prior to registration, defined as follows:\n\n  \\- Bilirubin \\\u003C 2 mg\u002Fdl o AST or ALT \\\u003C 3 x the upper limit of normal\n* Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential\n\nExclusion Criteria:\n\n* Metastatic disease\n* Non-HPV16 genotype (i.e. HPV-18,-31, -33, -35)\n* Patients who receive surgery at outside institution. Exceptions can be made for high-volume surgical centers at the discretion of the PI\u002Fco-PI\n* Prior head and neck radiation\n* Patients without pre-operative HPV ctDNA or pre-operative HPV ctDNA ≤ 50 copies\u002FmL\n* Subjects with simultaneous primary cancers outside of the oropharynx\n\n  o Note: Exceptions can be made for patients with simultaneous primaries outside of the oropharynx if determined by the PI\u002FCo-PI, then the patient can proceed with protocol activities\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years is 90% or greater\n\n  o Note: Exceptions can be made for patients with prior invasive malignancy if determined by the PI\u002FCo-PI, then the patient can proceed with protocol activities\n* Prior systemic chemotherapy for the study cancer\n\n  o Note: prior chemotherapy for a different cancer is allowable\n* Severe, active co-morbidity defined as follows:\n\n  * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months\n  * Transmural myocardial infarction within the last 6 months\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 30 days of registration\n  * Hepatic insufficiency resulting in clinical jaundice and\u002For coagulation defects\n* Lack of ability to understand and willingness to sign a written informed consent and complete questionnaires.",{"count":380,"type":22},[350],"This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their disease, or they will be scheduled to have this surgery.\n\nIn Arm A the researchers will see whether monitoring participants' HPV ctDNA levels can safely identify patients who do not need radiation therapy (RT) after surgery and whose RT can be delayed until their HPV ctDNA levels become detectable.\n\nIn Arm B, the researchers will see whether patients who usually need 6-6.5 weeks of CRT can be selected by HPV ctDNA to receive 3 weeks of CRT.",[29,408,409,410,411],"Oropharynx Cancer","HPV-Related Carcinoma","HPV-Related Malignancy","HPV Positive Oropharyngeal Squamous Cell Carcinoma",[413,414,415,416,361],"ctDNA","NavDx test","21-434","HPV-OPC","2026-04-10",{"date":419,"type":47},"2026-04-13",{"date":421,"type":47},"2022-03-24",{"date":423,"type":22},"2027-03-24",{"name":361,"class":90},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":114,"sex":61,"minAge":144,"maxAge":63,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":434,"conditions":435,"keywords":443,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":53},"100608318","impact-of-internal-menstrual-protections-on-immunity-and-vaginal-microbiota-100608318","NCT07199998","Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota","Impact of the Use of Internal Menstrual Protections on Immunity and Vaginal Microbiota","CUPS2","Inclusion Criteria:\n\n* Willingness to comply with all study procedures and availability for the duration of the study.\n* Female, aged 18 to 49 years.\n* In general good health, as determined by medical history.\n* Covered by the national health insurance system.\n* Willing to sign a written informed consent form.\n* Has already experienced menstruation prior to the start of the study.\n* No vaginal sexual intercourse within 72 hours before the study visit.\n* Has had at least 6 menstrual periods in the past 12 months.\n\nExclusion Criteria:\n\n* HIV infection.\n* Positive diagnosis for chlamydia or syphilis at screening or within 4 weeks prior to screening.\n* History of hormonal disorders or menstrual cycle irregularities.\n* Metrorrhagia.\n* Pregnancy or breastfeeding.\n* Family members or close relatives of the clinical or scientific team.\n* Treatment with any medication for chronic inflammatory disease or chronic conditions (e.g., cancer, arthritis, transplantation) within the past 12 months.\n* Participation in an ongoing clinical trial.\n* Receiving or having received antibiotic treatment within the 4 weeks prior to the study.\n* Refusal to be informed in case of detected abnormalities.\n* Indistinct use of both tampons and menstrual cups.\n* Never having had vaginal penetrative intercourse.",{"count":97,"type":22},"The availability, effectiveness, and safety of menstrual protection represent a key public health issue. However, research on women's menstrual and sexual health remains extremely limited. Whether societal or pathological, many hypotheses are emerging regarding the effects of menstrual protection products, yet little attention has been given to the products themselves, their societal role, or their physiological and pathological consequences. Internal menstrual products, such as tampons and menstrual cups, are widely used but are subject to limited regulatory oversight, and few studies have investigated their long-term effects on vaginal health.\n\nThis study aims to investigate how different types of menstrual protection influence vaginal microbiota, immune responses, and the recurrence of gynecological conditions such as bacterial vaginosis, mycosis, or dysbiosis. Biological samples (vaginal, cervical, urinary, and blood) will be collected to analyze vaginal microbiota composition and local immunity. Participants will be divided into three groups based on their main type of menstrual protection: menstrual cup users, tampon users, and external pad users. The study will compare these groups to assess potential differences in vaginal health and immune response related to menstrual product use.",[436,437,438,439,29,440,441,442],"Sexual Transmitted Disease","Vaginosis, Bacterial","Mycosis","Urogenital Disease","Dysbiosis","Toxic Shock Syndrome","Menstrual Cup",[444,440,445,446,447,448,35],"Menstrual cup","Menstrual health","Menstrual protection","Menstrual pad","Tampon","2026-04-08",{"date":451,"type":47},"2026-04-09",{"date":453,"type":47},"2026-04-07",{"date":455,"type":22},"2027-03",{"name":457,"class":90},"Centre National de la Recherche Scientifique, France",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":61,"minAge":144,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":467,"conditions":468,"keywords":472,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":53},"100630919","hpv-after-chemoradiotherapy-100630919","NCT07493928","HPV After chemoRadioTherapy","Implementation of HPV Testing in Patients After Radiotherapy for Cervical Cancer","HART","Inclusion Criteria:\n\n* Patient indicated for primary RT for cervical cancer\n* FIGO stage IB - IVA\n* Signed informed consent\n* Age ≥ 18 years\n* Administration of RT with curative intent\n\nExclusion Criteria:\n\n* Clinical stage FIGO IA\n* Clinical stage FIGO IVB\n* History of radiotherapy in the pelvis\n* Hysterectomy performed before the start of radiotherapy (adjuvant RT)\n* History of HPV-associated malignancy in personal history\n* HIV or other significant immunodeficiency",{"count":147,"type":22},"The HART (HPV After chemoRadiotherapy) study is a prospective multicenter observational trial designed to evaluate the clinical utility of HPV testing in the follow-up of patients treated with definitive chemoradiotherapy (CRT) for cervical cancer. Current surveillance after CRT relies mainly on clinical examination and imaging, while the role of HPV-based molecular monitoring remains insufficiently defined. The study plans to enroll 120 patients with FIGO stage IB-IVA cervical cancer treated with primary radiotherapy with curative intent. HPV detection will be performed using two complementary approaches: PCR-based detection of HPV DNA from a cervical swab and analysis of circulating HPV tumor DNA (ctDNA) in peripheral blood. Samples will be collected before treatment and during follow-up at 3, 12, and 24 months after completion of CRT. The primary objective is to determine the sensitivity of these methods for detecting disease recurrence during a two-year follow-up period. Secondary objectives include evaluation of HPV clearance after treatment, comparison of HPV genotypes before and after therapy in cases of persistence, and comparison of the diagnostic performance of cervical HPV testing and ctDNA detection. The study aims to generate evidence supporting the integration of HPV-based molecular monitoring into routine follow-up, potentially enabling earlier detection of recurrence and more individualized surveillance strategies for patients after CRT for cervical cancer.",[469,470,471,29],"Cervical Cancer Recurrent","Radiotherapy","Cell Free DNA",[473,474,475],"cervical cancer","cfDNA","radiotherapy","2026-03-20",{"date":478,"type":47},"2026-03-25",{"date":480,"type":47},"2026-02-01",{"date":482,"type":22},"2030-02-01",{"name":484,"class":90},"General University Hospital, Prague",{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":66,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":53},"100416590","feasibility-study-of-ocular-surface-squamous-neoplasia-surgical-excision-in-people-living-with-hiv-in-sub-saharan-africa-100416590","NCT04704648","Feasibility Study of Ocular Surface Squamous Neoplasia Surgical Excision in People Living With HIV in Sub-Saharan Africa","Feasibility Study of Ocular Surface Squamous Neoplasia (OSSN) Surgical Excision in People Living With HIV in Sub-Saharan Africa (SSA)","Inclusion Criteria:\n\n3.2.1 Participants with suspected unilateral, non-invasive OSSN lesions that the AMC-certified ophthalmologist determines can be resected with 3 mm clinical margins, sparing involvement of the superior and inferior fornices as well as 6 clock hours of the corneal scleral limbus. This assessment must be carried out within 4 weeks before surgery.\n\n3.2.2 HIV positive. Documentation of HIV-1 infection by means of any one of the following:\n\n* Documentation of receipt of ART by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Antiretroviral drug regimens used for pre-exposure prophylaxis (PrEP) may not satisfy this requirement.;\n* HIV-1 RNA detection by a licensed HIV-1 RNA assay demonstrating \\>1000 RNA copies\u002FmL confirmed by a licensed screening antibody and\u002For HIV antibody\u002Fantigen combination assay;\n* Any licensed HIV screening antibody and\u002For HIV antibody\u002Fantigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay.\n\nNote: The term \"licensed\" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally (e.g., U.S. FDA).\n\nWHO and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an enzyme or chemiluminescence assay (E\u002FCIA) that is based on a different antigen preparation and\u002For different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load.\n\n3.2.3 Performance status ≤ 2 on the WHO Scale (see Appendix III).\n\nExclusion Criteria:\n\n3.3.1 Participants who are receiving any other investigational agents within 30 days before enrollment for surgery, except for investigational ART regimens, which will be permitted.\n\n3.3.2 Participants with known history of ocular surface lesions including OSSN, other ocular neoplasm, pterygia, or limbal vernal keratoconjunctivitis.\n\n3.3.3 Uncontrolled intercurrent illness within 4 weeks before enrollment, including but not limited to ongoing or active infection, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":493,"type":22},84,[68],"Participants will undergo surgical excision of OSSN at baseline and will be followed at 1 week, 6 weeks, 6 months, and 12 months for post-surgical follow up. This study is being conduced to assess the feasibility of conducting multi-center prospective studies on surgical excision of suspected OSSN lesions in SSA in people living with HIV\u002FAIDS (PLWHA). Participants include those with HIV infection and with suspected non-invasive OSSN lesions that the AMC-certified ophthalmologist determines can be resected with 3 mm clinical margins, sparing involvement of the superior and inferior fornices and 6 clock hours of the corneal scleral limbus.",[497,29],"Ocular Surface Squamous Neoplasia","2026-03-19",{"date":500,"type":47},"2026-03-23",{"date":502,"type":47},"2023-06-21",{"date":504,"type":22},"2027-12-30",{"name":506,"class":507},"AIDS Malignancy Consortium","NETWORK",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":513,"targetDuration":4,"studyType":66,"phases":514,"briefSummary":515,"conditions":516,"keywords":517,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":524,"locationsCount":53},"100628980","feasibility-study-comparing-use-of-one-or-two-probes-for-thermal-ablation-among-cervical-cancer-screen-positive-women-living-with-hiv-in-c1001p-cs2-kenya-100628980","NCT07468695","Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS2 Kenya",{"count":97,"type":22},[68],"Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. In Kenya, the estimated incidence rate of cervical cancer is 31-33 per 100,000 women per year among women without HIV and approximately 70-100 per 100,000 among WLWH.\n\nThe proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030.",[71,29,72],[75,76,77,78,79],"2026-03-09",{"date":520,"type":47},"2026-03-12",{"date":522,"type":22},"2026-03",{"date":87,"type":22},{"name":89,"class":90},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":532,"enrollmentInfo":533,"targetDuration":4,"studyType":66,"phases":535,"briefSummary":536,"conditions":537,"keywords":542,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":550,"locationsCount":53},"100591342","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-papillex-on-abnormal-cervical-cells-caused-by-hpv-100591342","NCT06979180","A Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV.","A Randomized, Triple-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Papillex® on Abnormal Cervical Cells Caused by HPV","Inclusion Criteria:\n\n1. Females between 25 and 55 years of age\n2. Females not of child-bearing potential, defined as those who have undergone a permanent sterilization procedure (e.g. hysterectomy, bilateral oophorectomy or bilateral tubal occlusion) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), hormone implant (Norplant System) or intrauterine hormone-releasing system\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomized partner, provided that partner is the sole sexual partner and that the vasectomised partner has received medical assessment of the surgical success\n   * Abstinence\n3. Histologically confirmed CIN1+ (as per standard of care) with concordant hrHPV positivity at that time, and current abnormal cytology and hrHPV positivity at screening; interval between historical diagnosis and screening must be \\>12 months OR documented abnormal cytology (LSIL or worse) plus hrHPV positive \\>12 months prior, and current abnormal cytology with hrHPV positivity at screening\n4. Willing to provide copies of histology and\u002For cytology reports for eligibility confirmation\n5. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n6. Willingness to avoid magnetic resonance imaging, computed tomography, X-ray, or other procedures with contrast media injection for 48 hr prior to study visits assessing micronutrient status\n7. Willingness and ability to complete questionnaires and diaries associated with the study, and to complete all clinic visits and assessments\n8. Provided voluntary, written, informed consent to participate in the study\n9. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Women who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance preventing consumption of investigational product or placebo ingredients\n3. Currently undergoing treatment for CIN, are indicated for treatment during the study period, have received treatment (e.g., conization or loop electrosurgical excision procedure) within the last five years, or have active CIN 3\n4. Concurrent uterine pathologies\n5. History of hysterectomy or destructive therapy of the cervix\n6. Cervical cancer\n7. Unstable metabolic disease or chronic diseases as assessed by the QI\n8. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)\n10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n11. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n15. Individuals with an autoimmune disease or are immune compromised\n16. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n17. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n18. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n19. Alcohol or drug abuse within the last 12 months\n20. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Section 7.3)\n21. Clinically significant abnormal laboratory results at screening as assessed by the QI\n22. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n23. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n24. Individuals who are cognitively impaired and\u002For who are unable to give informed consent\n25. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","55 Years",{"count":534,"type":22},60,[68],"The goal of this clinical trial is to investigate the safety and efficacy of Papillex® on the regression of abnormal cervical cells caused by HPV in women with a cervical intraepithelial neoplasia (CIN) 1 or 2 diagnosis. The main question it aims to answer is:\n\nIs there a difference in the proportion of participants with a regression in CIN based on histology or cytology from baseline at day 180 between Papillex® and placebo?\n\nParticipants will be asked to consume Papillex® or placebo for 180 days, complete questionnaires, a PAP smear, HPV test, and colonoscopy (where applicable).",[538,539,540,29,541],"CIN - Cervical Intraepithelial Neoplasia","CIN 1","CIN 2","Cervical Cells",[543,29,544],"Cervical intraepithelial neoplasia","Papillex","2026-03-03",{"date":547,"type":47},"2026-03-05",{"date":522,"type":22},{"date":270,"type":22},{"name":551,"class":552},"Papillex Inc.","INDUSTRY",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":66,"phases":562,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":53},"100597987","phase-2-response-adaptive-treatment-in-untreated-locoregional-hpv-negative-head-and-neck-cancer-100597987","NCT07065630","Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer","A Phase II Study of Volrustomig, Paclitaxel, and Carboplatin Followed by Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer","Inclusion Criteria:\n\n* Patients must have pathologically confirmed locally advanced, non-metastatic, head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, nasopharynx, larynx, or sinuses.\n\n  * If a primary oropharyngeal squamous cell carcinoma is diagnosed, HPV must be ruled out by immunohistochemistry (defined as negative immunohistochemical staining of p16)\n  * Non-oropharyngeal primary sites do not require immunohistochemical or other means of testing for HPV status, however if they are performed, must be negative for HPV.\n  * Nasopharyngeal primary must have both EBV and HPV ruled out by immunohistochemistry to be eligible.\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n* Stage IV disease with the exception of nasopharyngeal primary T3N2 (stage III) based of AJCC staging 8th edition.\n* Patients must have measurable disease per RECIST 1.1 criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. See Section 11 for the evaluation of measurable disease.\n* No previous radiation, chemotherapy, or immunotherapy for a head and neck cancer.\n* Age ≥18 years.\n* ECOG performance status of 0 or 1.\n* Patients must have adequate organ and marrow function as defined below\n\n  * Leukocytes ≥3,000\u002FmcL\n  * Absolute neutrophil count ≥ 1.5 × 109\u002FL (1,500 per mm3)\n  * Platelet count ≥ 100 × 109\u002FL (100,000 per mm3)\n  * Hemoglobin ≥ 9.0 g\u002FdL (5.59 mmol\u002FL)\n  * Total bilirubin ≤ 1.5 × ULN in the absence Gilbert's syndrome ≤ 3×ULN if the subject has Gilbert's syndrome\n  * Alanine transaminase and aspartate transaminase ≤ 3 × ULN\n  * LVEF as assessed by echocardiography or multiple-gated acquisition scan ≥ 50%\n  * Troponin I or T≤ ULN (institutional guidelines and\u002For not clinically significant per investigator judgement)\n  * QTcF ≤ 480 msec\n  * Creatinine within normal institutional limits OR eGFR (using CKD-EPI equation)≥45 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* No complete surgical resection for a head and neck cancer within 8 weeks of enrollment (although lymph node biopsy including excision of an individual node with presence of residual nodal disease, or surgical biopsy\u002Fexcision of the tumor with residual measurable disease is acceptable.) No surgical procedures will occur after baseline scans are performed and measurable lesions are identified, although fine needle aspiration or core needle biopsies can be performed without need to repeat baseline scans before starting treatment if otherwise within screening window.\n* The effects of volrustomig on the developing human fetus are unknown. For this reason and because anti-PD1\u002Fanti-CTLA4 agents as well as other therapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of volrustomig administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Unequivocal demonstration of distant metastatic disease (M1 disease).\n* Unidentifiable primary site.\n* Prior surgical therapy other than incisional\u002Fexcisional biopsy or organ-sparing procedures such as debulking of airway-compromising tumors. Residual measurable tumor is required for enrollment as discussed above.\n* Patients who are receiving any other investigational agents.\n* Patients with a \"currently active\" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for ≥ 3 years. Exceptions include other cancers that have undergone potentially curative therapy or in situ cervical cancer or any tumors that are not likely to influence life expectancy in the subsequent 3 years without active treatment.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to volrustomig or other agents used in study.\n* Patients with uncontrolled intercurrent illness.\n* Negative pregnancy test (urine or serum) for female subjects of childbearing potential. Female subjects must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of volrustomig to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used. Pregnant women are excluded from this study because volrustomig is an anti-PD1\u002Fanti-CTLA4 agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with volrustomig, breastfeeding should be discontinued if the mother is treated with volrustomig. These potential risks may also apply to other agents used in this study.\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of Volrustomig monotherapy.\n* Male subjects must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of Volrustomig to prevent pregnancy in a partner.\n* Intercurrent medical illnesses which would impair patient tolerance to therapy or limit survival. This includes but is not limited to ongoing or active infection, immunodeficiency, specified cardiac conditions (below), pulmonary dysfunction, cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance. Patients with clinically stable and\u002For chronically managed medical illnesses that are not symptomatic and\u002For are not expected to impact treatment on protocol are still eligible.\n* Any of the following cardiac conditions:\n\n  * Cardiomyopathy of any etiology or history of myocarditis\n  * Heart failure (as defined by New York Heart Association class III-IV)\n  * Uncontrolled hypertension\n  * Unstable angina pectoris\n  * Clinically significant coronary, carotid, or peripheral artery stenosis\n  * Acute coronary syndrome\u002Facute myocardial infarction and\u002For coronary intervention with PCI\u002FCABG within 12 months prior to randomization\n  * Prior arterial or peripheral vascular intervention within 12 months prior to randomization\n  * Ventricular arrhythmias requiring treatment, high degree AV block (II-III), or sinus node dysfunction with significant sinus pause, untreated with pacemaker. Note: Patients with atrial fibrillation or flutter who are clinically stable and have an optimally controlled ventricular rate (eg, mean of \\\u003C 100 bpm on resting ECG or 24-h Holter-ECG) may be eligible if all other cardiac eligibility criteria are met, and a cardiology assessment confirms suitability for study treatment.\n  * History of QT prolongation associated with other medications that required discontinuation of that medication.\n  * Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.\n  * Planned or scheduled cardiac surgery or percutaneous coronary intervention procedure.\n  * Planned revascularization procedure within 6 months of randomization.\n* Evidence of the following infections:\n\n  * Active infection including tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination, and radiographic findings and TB testing in line with local practice).\n  * Uncontrolled human immunodeficiency virus (HIV) infection; the following criteria are required to define well-controlled HIV infection:\n  * undetectable viral RNA load for 6 months, CD4+ count of \\>500 cells\u002FμL, stable for at least 6 months on the same anti-HIV medications, and no history of AIDS (defined by either CD+T cell count \\\u003C200 cells\u002FμL and\u002For AIDS-defining opportunistic infection)\n  * Active or uncontrolled hepatitis B (HBV) or hepatitis C (HCV); Participants are eligible if they:\n  * Have controlled hepatitis C viral load defined as undetectable hepatitis C RNA by PCR either spontaneously or in response to a successful prior course of anti-hepatitis C therapy\n  * Have received HBV vaccination with only anti-HBs positivity and no clinical signs of hepatitis\n  * Are HBsAg negative and anti-HBc+ (ie, those who have cleared HBV after infection) and meet conditions i-iii below:\n  * Are HBsAg positive with chronic HBV infection (lasting 6 months or longer) and meet conditions i-iii below:\n  * HBV DNA viral load \\\u003C100 IU\u002FmL\n  * Have normal transaminase values Start or maintain antiviral treatment if clinically indicated as per the investigator. These patients will receive repeat testing at least every 6 months to assess for reactivation.\n  * Active hepatitis A\n* Diagnosis of immunodeficiency or is receiving systemic steroid therapy in excess of physiologic dose or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment.\n\nThe following are exceptions to this criterion:\n\n* Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n* Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n* Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n\n  -Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n* Patients with vitiligo or alopecia\n* Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n* Any chronic skin condition that does not require systemic therapy\n* Patients without active disease in the last 5 years may be included but only after consultation with the study physician\n* Patients with celiac disease controlled by diet alone.\n\n  * History of allogenic organ transplantation.\n  * Has known history of, or any evidence of active, non-infectious pneumonitis.\n  * Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 90 days after the last dose of IP.\n  * Subjects who are blood donors should not donate blood during the study and for 3 months following their last dose of volrustomig.",{"count":561,"type":22},38,[350],"The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma\n\n.",[565,29],"Head and Neck Cancer","2026-03-02",{"date":568,"type":47},"2026-03-04",{"date":570,"type":47},"2025-10-07",{"date":572,"type":22},"2029-08-13",{"name":574,"class":90},"University of Chicago",{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":66,"phases":583,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":396},"100524526","prevencin-en-sus-manos-feasibility-of-a-novel-community-based-strategy-to-improve-access-to-cervical-cancer-screening-100524526","NCT06109870","Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent form\n* Currently resident in RGV or other low-resource community in Texas\n* Stated willingness to comply with all study procedures\n* Females; Age ≥25 years\n* Have no history of hysterectomy with removal of the cervix\n* Have no history of cervical cancer or high-grade dysplasia\n* Have not had a Pap test in the past 3.5 years or Pap\u002FHPV co-test in the past 5.5 years.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Unable to communicate in English or Spanish\n* Lack valid telephone contact information\n* Report being currently pregnant.",{"count":582,"type":22},920,[68],"Cervical cancer is a disease that is preventable through vaccination against the virus that causes it, human papillomavirus (HPV), and through screening and treatment of cervical disease before it becomes cancet.",[29],{"date":568,"type":47},{"date":588,"type":47},"2023-10-30",{"date":590,"type":22},"2030-08-31",{"name":592,"class":90},"M.D. Anderson Cancer Center",{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":61,"minAge":301,"maxAge":302,"enrollmentInfo":600,"targetDuration":4,"studyType":66,"phases":601,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":396},"100626626","concordance-and-acceptability-of-self-screening-compared-to-screening-carried-out-by-a-health-professional-for-hpv-a-risk-factor-for-anal-cancer-by-swab-in-people-living-with-hiv-a-randomized-controlled-crossover-study-100626626","NCT07438080","Concordance and Acceptability of Self-screening Compared to Screening Carried Out by a Health Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV. A Randomized Controlled Crossover Study","ALONDEPISTHPV","Inclusion Criteria:\n\n* Aged 30 to 65,\n* In a vulnerable situation (beneficiary of a state or departmental social service, or referred by a charity),\n* Resident in one of the two municipalities targeted by the study,\n* Supported by the social services of one of the two municipalities targeted by the study,\n* Having agreed to participate in sexual health awareness meetings organized on site\n\nExclusion Criteria:\n\n* Refusing to participate in the study\n* Having had a hysterectomy",{"count":97,"type":22},[68],"Comunity health actions are set up in populations of women aged 30 to 65 in vulnerable situations living in the outlying areas of Reunion Island.\n\nThe idea is to evaluate those action on health",[29],"2026-02-26",{"date":606,"type":47},"2026-02-27",{"date":608,"type":47},"2025-04-09",{"date":610,"type":22},"2028-03-01",{"name":612,"class":90},"Centre Hospitalier Universitaire de la Réunion",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":61,"minAge":144,"maxAge":620,"enrollmentInfo":621,"targetDuration":18,"studyType":23,"phases":4,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":53},"100527409","regression-of-cervical-precancerous-lesions-and-associated-risk-factors-100527409","NCT06147388","Regression of Cervical Precancerous Lesions and Associated Risk Factors","RECER","Inclusion Criteria:\n\n1. squamocolumnar junction fully visualized\n2. bioptically verified CIN 2 or CIN 3\n3. age ≥ 18 years\n4. age ≤ 40 years\n5. informed consent\n\nExclusion Criteria:\n\n1. squamocolumnar junction not fully visualized\n2. suspicion on glandular lesion\n3. suspicion on invasive cancer\n4. personal history of CIN 2, 3 or cerv. cancer\n5. gravidity\n6. HIV positivity\n7. immunosuppression\n8. impossible photographic documentation","40 Years",{"count":97,"type":22},"The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normalization of HPV test and cytology finding among those who were treated conservatively and those who underwent conization; and identify predictive parameters associated with regression. Based on this analysis, a model will be proposed to predict the likelihood of lesion regression.",[624,29,625,626],"Cervix Uteri SIL","CIN2","CIN3","2026-02-22",{"date":629,"type":47},"2026-02-25",{"date":631,"type":47},"2022-09-01",{"date":633,"type":22},"2027-07-01",{"name":484,"class":90},{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":114,"sex":61,"minAge":62,"maxAge":302,"enrollmentInfo":641,"targetDuration":4,"studyType":66,"phases":643,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":652,"locationsCount":53},"100567937","hpv-self-collection-program-100567937","NCT06674681","HPV Self-Collection Program","Inclusion Criteria:\n\n* Women and individuals with a cervix.\n* Aged 25-65 years during the study measurement period.\n* Qualifying visit to the participating clinic.\n* Overdue for cervical cancer screening.\n* Those aged 24-64 who have not had cervical cytology (i.e., Pap test) performed within the last three and a half (3.5) years, or those aged 30-65 who have not had cervical HPV testing (i.e., primary HPV testing or contesting for HPV with Pap test) performed within the last five and a half (5.5) years.\n\nExclusion Criteria:\n\n* Individuals without a cervix.\n* Receiving hospice and\u002For palliative care during any part of the measurement period.",{"count":642,"type":22},1000,[68],"The objective of the study is to develop, pilot, and analyze the effectiveness of HPV self-collection programs which will be used to follow up among women overdue for cervical cancer screening. The investigators will develop protocols for in-clinic and home-based HPV-self-collection programs and follow-up system for HPV-positive tests for community health centers and\u002For clinics. The program is meant to mail HPV-self-collection kits to women who are due and\u002For overdue for cervical cancer screening and the program is also meant to present women seen in clinic with a self-collection option for screening alongside a Pap test option. The research team will develop related informational resources on how to complete the test as well as information on screening options.\n\nThe study will neither experiment nor test the effectiveness of the self-collection process nor the assay of specimens for HPV and high-risk HPV strains. It is not a clinical investigation to assess the safety or effectiveness of a medical device. The study is implementation science and seeks to find optimal ways to implement this World Health Organization recommended screening option.",[29],"2026-02-17",{"date":648,"type":47},"2026-02-20",{"date":650,"type":47},"2024-10-18",{"date":270,"type":22},{"name":653,"class":90},"University of Utah"]